Redmile Group LLC Buys 668,080 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Redmile Group LLC raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 5.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,043,932 shares of the biopharmaceutical company’s stock after buying an additional 668,080 shares during the period. Amicus Therapeutics makes up about 7.4% of Redmile Group LLC’s investment portfolio, making the stock its 2nd largest holding. Redmile Group LLC owned approximately 7.32% of Amicus Therapeutics worth $121,282,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Teacher Retirement System of Texas increased its holdings in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 169 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co bought a new position in shares of Amicus Therapeutics in the second quarter valued at $111,000. Tudor Investment Corp ET AL bought a new position in shares of Amicus Therapeutics in the second quarter valued at $124,000. Aperio Group LLC increased its holdings in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,663 shares in the last quarter. Finally, Zacks Investment Management bought a new position in shares of Amicus Therapeutics in the second quarter valued at $145,000.

Amicus Therapeutics, Inc. (NASDAQ FOLD) traded down 0.305% during trading on Tuesday, hitting $14.695. 540,925 shares of the stock traded hands. The company’s 50 day moving average is $14.39 and its 200 day moving average is $10.90. The company’s market capitalization is $2.42 billion. Amicus Therapeutics, Inc. has a one year low of $4.41 and a one year high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03. The company had revenue of $7.16 million for the quarter, compared to analyst estimates of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same period in the prior year, the firm posted ($0.40) EPS. On average, equities analysts forecast that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.

WARNING: “Redmile Group LLC Buys 668,080 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://ledgergazette.com/2017/10/17/redmile-group-llc-grows-holdings-in-amicus-therapeutics-inc-fold.html.

In other Amicus Therapeutics news, insider Hung Do sold 50,194 shares of the company’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $715,264.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Michael Raab sold 10,000 shares of the company’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $142,500.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 107,194 shares of company stock worth $1,527,515. 3.40% of the stock is owned by insiders.

Several analysts have issued reports on the stock. Leerink Swann reissued an “outperform” rating and set a $17.00 target price (down from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. BidaskClub downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 2nd. Cowen and Company reissued a “buy” rating and set a $16.00 target price (up from $10.00) on shares of Amicus Therapeutics in a research note on Tuesday, July 11th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $17.00 target price on shares of Amicus Therapeutics in a research note on Friday, October 6th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to t

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Teacher Retirement System of Texas increased its holdings in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 169 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co bought a new position in shares of Amicus Therapeutics in the second quarter valued at $111,000. Tudor Investment Corp ET AL bought a new position in shares of Amicus Therapeutics in the second quarter valued at $124,000. Aperio Group LLC increased its holdings in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,663 shares in the last quarter. Finally, Zacks Investment Management bought a new position in shares of Amicus Therapeutics in the second quarter valued at $145,000.

Amicus Therapeutics, Inc. (NASDAQ FOLD) traded down 0.305% during trading on Tuesday, hitting $14.695. 540,925 shares of the stock traded hands. The company’s 50 day moving average is $14.39 and its 200 day moving average is $10.90. The company’s market capitalization is $2.42 billion. Amicus Therapeutics, Inc. has a one year low of $4.41 and a one year high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03. The company had revenue of $7.16 million for the quarter, compared to analyst estimates of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same period in the prior year, the firm posted ($0.40) EPS. On average, equities analysts forecast that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.

WARNING: “Redmile Group LLC Buys 668,080 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://ledgergazette.com/2017/10/17/redmile-group-llc-grows-holdings-in-amicus-therapeutics-inc-fold.html.

In other Amicus Therapeutics news, insider Hung Do sold 50,194 shares of the company’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $715,264.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Michael Raab sold 10,000 shares of the company’s stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $142,500.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 107,194 shares of company stock worth $1,527,515. 3.40% of the stock is owned by insiders.

Several analysts have issued reports on the stock. Leerink Swann reissued an “outperform” rating and set a $17.00 target price (down from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. BidaskClub downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 2nd. Cowen and Company reissued a “buy” rating and set a $16.00 target price (up from $10.00) on shares of Amicus Therapeutics in a research note on Tuesday, July 11th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $17.00 target price on shares of Amicus Therapeutics in a research note on Friday, October 6th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Amicus Therapeutics currently has an average rating of “Buy” and an average price target of $17.81.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply